Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment

Paola Terlizzese, Fabrizio Losurdo, Massimo Iacoviello, Nadia Aspromonte

Research output: Contribution to journalReview article

Abstract

Recently, great attention is paid to cardiovascular impact of non-insulin glucose-lowering drugs, particularly in terms of major cardiovascular events and risk of heart failure. In this regard, a surprising diversity among different molecules within the same pharmacological class has been noticed, yielding to an intra-class discrepancy which has no analogous in other cardiovascular fields. The aim of this paper is to review the literature, giving an insight of the heterogeneous effects among groups and within group shown by oral antidiabetic drugs, with a special concern to fragile patients, such as those with or at risk of heart failure.

Original languageEnglish
Pages (from-to)469-479
Number of pages11
JournalHeart Failure Reviews
Volume23
Issue number3
DOIs
Publication statusPublished - May 1 2018

Keywords

  • Alpha-glucosidase inhibitors
  • Biguanides
  • Diabetes
  • GLP-1 agonists
  • Heart failure
  • Oral antidiabetic drugs
  • SGLT-2 inhibitors
  • Sulfonylureas
  • Thiazolidinediones

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment'. Together they form a unique fingerprint.

  • Cite this